Lung Cancer
Publication details: New Jersey : Wiley, 2014Edition: 4thISBN:- 1118468740
- 9781118468746
Item type | Home library | Class number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|
Book | David Adams Library (Royal Marsden) Shelves | WF658 ROT (Browse shelf(Opens below)) | Available | 0000006971 |
Browsing David Adams Library (Royal Marsden) shelves, Shelving location: Shelves Close shelf browser (Hides shelf browser)
WF658 MUE The effective management of lung cancer | WF658 PAS Lung cancer : principles and practice | WF658 PET Nicotine and tobacco dependence | WF658 ROT Lung Cancer | WF658 SCU Malignant tumors of the lung : evidence-based management | WF658 SYR Tumors of the chest : biology, diagnosis and management | WF658 SYR Tumors of the chest : biology, diagnosis and management |
Smoking prevention and cessation; Lung cancer susceptability and risk assessment models; Molecular profiling; Somatic genome alterations in human lung cancers; Serum proteomic biomarkers; Molecular biology of lung preneoplasia; Detection and treatment of preneoplastic lesions; Pathology of adenocarcinoma; Management of multifocal bronchioloalveloar carcinoma (BAC); Radiology and lung cancer screening; Imaging lung cancer; Staging of the medastinum; Managing of the solitary pulmonary nodule; Minimally invasive resections for lung cancer; Extended resections for lung cancer; Bronchoscopic interventions for liung cancer; Primary tracheal tumors; Adjuvant chemotherapy following surgery for lung cancer; Neoadjuvant chemotherapy following resectle non-small cell lung cancer; Image-guided radiation therapy; Stereotactic ablative radiotherapy for lung cancer; Proton therapy; Combinations of radiation therapy and chemotherapy for non-small cell and small-cell lung cancer; Molecular target treatment for personalizaed radiotherapy in lung cancer; EGFR tyrosine kinase inhibitors and monoclonal antibodies: clinical trial review; Mechanisms to the resistance to epidermal drowth factor receptor (EGFR) in non-small cell lung cancer; Predictive tumor biomarkers for EGFR inhibitors; Immunologic approaches to lung cancer therapy; Novel and emerging agents in NSCLC; Novel clinical trial designs for metastatic lung cancer; Novel statistical models for NSCLC clinical trials; Tumor microenvironment, angiogenesis biology, and targeted therapy; Anti-angiogenic agents in metastatic NSCLC; Targeting ALK rearrangements; Non-small cell lung cancers (NSCLC) and mutations in BRAF; Prognostic and predictive biomarker signatures; Brain metastasis from lung cancer; Index
Here is the comprehensively revised, updated, and expanded edition of the wellestablished, evidencebased reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever featuring nine new chapters along with seven reformatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of MultiFocal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; NonSmall Cell and SmallCell Lung Carcinoma; and more.
There are no comments on this title.